ZAVESCA Drug Patent Profile

When do Zavesca patents expire, and when can generic versions of Zavesca launch?

Zavesca is a drug marketed by Actelion and is included in one NDA.

The generic ingredient in ZAVESCA is miglustat. There are two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the miglustat profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zavesca

A generic version of ZAVESCA was approved as miglustat by ANI PHARMS on April 17^th, 2018.

Summary for ZAVESCA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	54
Clinical Trials:	12
Patent Applications:	2,451
Drug Prices:	Drug price information for ZAVESCA
What excipients (inactive ingredients) are in ZAVESCA?	ZAVESCA excipients list
DailyMed Link:	ZAVESCA at DailyMed

See drug prices for ZAVESCA

Recent Clinical Trials for ZAVESCA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Actelion	Phase 4
Mashhad University of Medical Sciences	Phase 3
Kashan University of Medical Sciences	Phase 3

See all ZAVESCA clinical trials

Pharmacology for ZAVESCA

Drug Class	Glucosylceramide Synthase Inhibitor
Mechanism of Action	Glucosylceramide Synthase Inhibitors

US Patents and Regulatory Information for ZAVESCA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actelion	ZAVESCA	miglustat	CAPSULE;ORAL	021348-001	Jul 31, 2003	AB	RX	Yes	Yes

Expired US Patents for ZAVESCA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Actelion	ZAVESCA	miglustat	CAPSULE;ORAL	021348-001	Jul 31, 2003	5,472,969
Actelion	ZAVESCA	miglustat	CAPSULE;ORAL	021348-001	Jul 31, 2003	5,525,616

EU/EMA Drug Approvals for ZAVESCA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Piramal Critical Care B.V.	Yargesa	miglustat	EMEA/H/C/004016Yargesa is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease.Yargesa may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Yargesa is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.	Authorised	yes	no	no	2017-03-22
Janssen Cilag International NV	Zavesca	miglustat	EMEA/H/C/000435Zavesca is indicated for the oral treatment of adult patients with mild to moderate type-1 Gaucher disease. Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type-C disease.	Authorised	no	no	no	2002-11-20	2009-06-16
Gen.Orph	Miglustat Gen.Orph	miglustat	EMEA/H/C/004366Miglustat Gen.Orph is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease. Miglustat Gen.Orph may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Miglustat Gen.Orph is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.	Authorised	yes	no	no	2017-11-09
Dipharma Arzneimittel GmbH	Miglustat Dipharma	miglustat	EMEA/H/C/004904Miglustat Dipharma is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease.Miglustat Dipharma may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Miglustat Dipharma is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.	Authorised	yes	no	no	2019-02-18

International Patents for ZAVESCA

See the table below for patents covering ZAVESCA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	148456
Austria	268598
Australia	5813898
Australia	6783294

ZAVESCA (miglustat) Market Dynamics and Financial Trajectory: Exclusivity, Competitive Pressure, and Revenue Outlook

Last updated: July 30, 2026

ZAVESCA (miglustat, Actelion/Janssen) is a niche, orphan-priced oral therapy with a small treated-population base. Its commercial trajectory is dominated by (1) shrinking eligible patient segments, (2) competitive positioning from alternative enzyme replacement and substrate-reduction regimens in Gaucher disease and other rare indications, and (3) patent/exclusivity constraints that determine generic or licensed entry windows.

What market dynamics drive ZAVESCA (miglustat) revenue in Gaucher disease and other rare indications?

ZAVESCA is positioned for rare lysosomal storage disorders, with the commercial model built around specialty dispensing, treatment centers, payer authorization, and high per-patient net pricing relative to mainstream drugs. Revenue dynamics hinge on patient identification, diagnosis timing, and treatment-line sequencing.

How does treated-population size shape ZAVESCA’s revenue trajectory?

Because miglustat treats limited populations, revenue tends to move with:

• Incident diagnosis flow into the treated category (late diagnosed or treatment-ineligible subsets).
• Discontinuation rates tied to adverse event profiles and long-term tolerability.
• Shift in clinical practice toward competing standards (especially where alternatives show better tolerability, administration convenience, or outcomes).

What payer and contracting factors affect ZAVESCA net sales?

For orphan therapies like miglustat, payer behavior tends to:

• Require prior authorization and specialist documentation.
• Use indication- and line-of-therapy criteria that can tighten over time.
• Drive net price pressure via contracting in reference markets where multiple orphan options exist.

What competitive categories reduce ZAVESCA demand?

Competitive forces vary by indication, but commonly include:

• Enzyme replacement therapy (ERT) and next-generation ERT in Gaucher disease settings.
• Alternative substrate reduction therapy strategies (where available) that can capture eligible patients.
• Treatment-line substitution where patients transition away from miglustat after tolerability or efficacy comparisons.

How has ZAVESCA’s financial trajectory changed over time?

Financial trajectory for niche orphan drugs generally shows:

• Early growth linked to label expansion, center adoption, and contracting.
• Mid-life stabilization as diagnosis volumes and payer adoption mature.
• Late-cycle decline driven by patent expiry risk, substitution to other standards, and patient cohort aging.

For ZAVESCA specifically, the trajectory is constrained by:

• Orphan-market scale.
• Limited secondary commercialization levers (few new geographies or label expansions after establishment).
• The likelihood that much of its sales history is concentrated in mature markets with tight payer oversight.

When does ZAVESCA lose exclusivity, and what are the patent expiration dates that matter?

ZAVESCA exclusivity and patent timelines determine whether generic miglustat or licensed entrants can compete on price. For a complete and accurate exclusivity and patent-expiration map, the analysis must rely on ZAVESCA’s Orange Book listings and listed drug product patents for each dosage form (capsules), plus relevant exclusivity protections (e.g., orphan drug designation exclusivity where applicable).

No jurisdictional exclusivity and patent expiration dataset for ZAVESCA is provided in the request context. Without verified Orange Book / patent listing data, an expiration timeline cannot be stated without risking factual error.

What patents protect miglustat (ZAVESCA), and how strong is the patent estate?

A rigorous “how strong is the patent estate” view requires:

• Patent numbers, claims scope (composition, formulation, method of use, polymorphs, process claims).
• Filing and priority dates.
• Ownership/assignees.
• Claim construction risk and known validity or infringement rulings.

No patent-identification inputs or document set are included in the request. Without that dataset, the patent-coverage and strength analysis would be incomplete or potentially inaccurate.

What generic entry risks exist for ZAVESCA (miglustat)?

Generic entry risk depends on:

• Whether miglustat is already off-patent by the relevant jurisdiction.
• Whether Orange Book-listed patents were overcome via Paragraph IV filings or other mechanisms.
• Whether formulation or method-of-use patents persist for specific indications/dosage strengths.

No FDA Orange Book listing details or Paragraph IV filing history for ZAVESCA are included here. As a result, a credible entry-risk assessment cannot be produced.

What patent litigation or settlement agreements have affected ZAVESCA’s market access?

Patent litigation impacts:

• Timing of generic launch.
• Scope of “carve-outs” via settlements (e.g., specific strengths, indications, or patient subsets).
• Brand exclusivity continuity in the face of generic challenges.

No litigation docket information for ZAVESCA is provided in the request context. Without verified case references and dates, this section cannot be completed to a standard suitable for high-stakes R&D and investment decisions.

What is the Orange Book status of ZAVESCA (miglustat) in the US?

Orange Book status requires, at minimum:

• Listed drug name(s) and dosage forms.
• Orange Book application numbers (NDA/BLA).
• Patent numbers, expiration dates, and exclusivity codes.
• Whether patents are listed for method-of-use versus composition claims.

No Orange Book listing record for ZAVESCA is included. Without it, the Orange Book status cannot be stated.

How does ZAVESCA compare with competing Gaucher disease therapies on pricing and clinical positioning?

ZAVESCA’s market position is typically evaluated against:

• ERT competitors (administration, dosing schedule, outcomes, and adverse event profile).
• Alternative substrate reduction approaches (where available) with different tolerability and efficacy signals.
• Patient selection constraints that determine where miglustat is actually used.

Without specific pricing benchmarks and managed-care contracting data for each comparator in the same timeframe, a precise competitive price-performance ranking cannot be completed.

What manufacturing and IP barriers could limit generic or biosimilar-style competition?

For small-molecule miglustat, the generic barrier profile usually differs from biologics:

• Chemistry/manufacturing controls and impurity specifications tend to be the practical hurdles.
• IP barriers can include process claims, polymorph or formulation specifics, and method-of-use claims.
• Regulatory compatibility and bioequivalence implementation can determine the speed and probability of generic launches.

No ZAVESCA manufacturing-process patent data or formulation/IP barrier records are included in the request context, so this cannot be translated into actionable barriers.

Commercial outlook: what revenue drivers and downside risks will shape ZAVESCA going forward?

For a niche orphan oral therapy like miglustat, forward-looking performance typically tracks:

• Patient cohort stability and treatment switching patterns.
• Payer access stability and step-therapy tightening.
• Margin pressure from price competition if exclusivity ends or if therapeutic alternatives displace miglustat.

Key downside risks cluster around:

• Expanded substitution by alternative standards of care.
• Payer-driven net price compression as orphan portfolios mature.
• Any regulatory or labeling changes that alter patient eligibility.

Key revenue upside drivers are limited, typically tied to:

• Clinical-center prescribing persistence.
• Stable diagnosis rates within eligible subtypes.
• Favorable contracting.

A precise quantified revenue forecast requires historic net sales, unit volumes, geographic split, and explicit patent/exclusivity timing. Those inputs are not present.

Key Takeaways

• ZAVESCA (miglustat) operates as a niche orphan therapy where revenue is primarily driven by treated-population size, payer authorization dynamics, and treatment-line sequencing.
• Market pressure is structural: limited patient base plus substitution to other standards of care in rare disease.
• A high-confidence exclusivity, patent-expiration, Orange Book, generic-entry, and litigation impact assessment cannot be completed without verified Orange Book and patent/litigation datasets for ZAVESCA.

FAQs

1. Is ZAVESCA (miglustat) off-patent in the US, and when could generics launch?
2. Does ZAVESCA have method-of-use patents that block generic entry even if composition patents expire?
3. What are the most common payer hurdles that limit access to ZAVESCA in orphan drug contracts?
4. How do treatment guidelines influence miglustat’s share versus enzyme replacement therapy in Gaucher disease?
5. What formulation or manufacturing IP could delay generic miglustat development?

References

1. [No sources were provided in the request context.]